Nearly one in five pediatric hospital deaths in the United States involve sepsis, according to a new national study published ...
For every provider who switches from virtual human scribes to AI ambient voice scribes, the 100-provider Seattle group ...
NeurAxis, Inc. (AMEX:NRXS) Q4 2025 Earnings Call Transcript March 19, 2026 Operator: Ladies and gentlemen, thank you for standing by. Welcome to the NeurAxis, Inc. fourth quarter 2025 financial ...
Revenues increased 27% year over year to $968 thousand in 4Q25. Operating loss increased 17% year over year, primarily due to higher selling expenses directly related to increased sales volume and ...
Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced an update on the building momentum in the Company’s launch of FDA-approved ZEVASKYN (prademagene zamikeracel), a first-of-its-kind, autologous ...
A 230-basis-point gross margin decline in 2025 was attributed to higher discounting in financial assistance programs and ...
NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic ...
Abeona Therapeutics Inc (ABEO) reports growing patient demand and significant financial gains, despite facing operational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results